



September 29, 2022

BSE Limited

Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 (Listing Regulations).**

We are pleased to enclose a Press Release as regards, launch by the Company of Sildenafil for Oral Suspension, 10 mg/mL, having received approval from the U.S. FDA.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**Rajvardhan
Vishnu
Satam**

Digitally signed by Rajvardhan Vishnu Satam
DN: c=IN, st=Maharashtra,
2.5.4.20=c19d8f961d9f659e973a093a4d3924b2532eb2649
6ea7e2abcf74700f5375b7, postalCode=400104,
street=JADA SEJAL TOWERS SEJAL PARK LINK
ROAD, GOREGAON WEST, Mumbai, Mumbai
Nagar, Borivali, Mumbai Suburban,
pseudoym=Rakb7c271ba531ba56ed651dcbbef5b,
title=0191,
serialNumber=01ba6d6a6b6c796663c738ba253fa0b475d19
5f726cd67a2809c4242771b2a, o=Personal,
cn=Rajvardhan Vishnu Satam
Date: 2022.09.29 13:54:45 +05'30'

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl: a/a

Lupin Launches Sildenafil for Oral Suspension in the United States

Mumbai, Baltimore, September 29, 2022: Global pharma major Lupin Limited (Lupin) today announced the launch of Sildenafil for Oral Suspension, 10 mg/mL, having received an approval from the United States Food and Drug Administration (FDA).

Sildenafil for Oral Suspension, 10 mg/mL, is a generic equivalent of Revatio® for Oral Suspension, 10 mg/mL of Viatris Specialty LLC.

Sildenafil for Oral Suspension (RLD Revatio®) had estimated annual sales of USD 64 million in the U.S. (IQVIA MAT July 2022).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue in research and development in FY22.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

For further information or queries please contact –

Shweta Munjal

Vice President & Global Head – Corporate Communications

Email: shwetamunjal@lupin.com

***Safe Harbor Statement**

Revatio® is a registered trademark of Viatris Specialty LLC.